BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19461173)

  • 1. [Malignant lymphomas].
    Yamaguchi Y; Usui N
    Gan To Kagaku Ryoho; 2009 May; 36(5):736-41. PubMed ID: 19461173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma.
    Inwards DJ; Cilley JC; Winter JN
    Best Pract Res Clin Haematol; 2006; 19(4):669-84. PubMed ID: 16997176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy in malignant lymphoma.
    Coiffier B
    Oncogene; 2007 May; 26(25):3603-13. PubMed ID: 17530014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current controversies in follicular lymphoma.
    Aurora V; Winter JN
    Blood Rev; 2006 Jul; 20(4):179-200. PubMed ID: 16410034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas.
    Cilley J; Winter JN
    Haematologica; 2006 Jan; 91(1):114-20. PubMed ID: 16434379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease.
    Seyfarth B; Josting A; Dreyling M; Schmitz N
    Br J Haematol; 2006 Apr; 133(1):3-18. PubMed ID: 16512824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indolent lymphomas: current and emerging treatment approaches.
    Maloney D; Kahl BS; Dreyling M
    Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
    Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
    Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epratuzumab in the therapy of oncological and immunological diseases.
    Goldenberg DM
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1341-53. PubMed ID: 17069520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretargeted radioimmunotherapy for B-cell lymphomas.
    Green DJ; Pagel JM; Pantelias A; Hedin N; Lin Y; Wilbur DS; Gopal A; Hamlin DK; Press OW
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5598s-5603s. PubMed ID: 17875795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
    Mattes MJ; Sharkey RM; Karacay H; Czuczman MS; Goldenberg DM
    Clin Cancer Res; 2008 Oct; 14(19):6154-60. PubMed ID: 18829494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal antibodies for lymphomas and leukemias in 2005].
    Peffault de Latour R; Robin M; Bay JO
    Bull Cancer; 2006 Jan; 93(1):107-18. PubMed ID: 16455513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radio-immunotherapy for B-cell non-Hodgkin lymphoma].
    Visser OJ; Zijlstra JM; van Dongen GA; Huijgens PC
    Ned Tijdschr Geneeskd; 2005 Oct; 149(42):2324-8. PubMed ID: 16261710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
    Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Wang Y; Chang CH
    Cancer Res; 2008 Oct; 68(20):8384-92. PubMed ID: 18922911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary malignancies and quality of life after stem cell transplantation.
    Ortega JJ; Olivé T; de Heredia CD; Llort A
    Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S83-7. PubMed ID: 15812538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
    Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
    Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for central nervous system lymphomas in immunocompetent patients.
    Jahnke K; Thiel E
    Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
    Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.